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Background: Static and dynamic lung hyperinflation are associated with exercise impairment
and poor outcomes in COPD patients. Aclidinium bromide is a novel, long-acting inhaled
muscarinic antagonist currently in development for COPD treatment.
Methods: Patients with moderate to severe COPD (N Z 181) were randomized to once-daily
aclidinium 200 mg or placebo for 6 weeks. Constant work rate cycling exercises at 75% of peak
work rate were performed at baseline, Day 1, Week 3, and Week 6. The primary efficacy
measure was change in exercise endurance time (ET) from baseline to Week 6. Secondary
outcomes included changes in trough forced expiratory volume in 1 s (FEV1), inspiratory
capacity (IC), IC/total lung capacity (TLC), and functional residual capacity (FRC) from base-
line to Day 1, Week 3, and Week 6. Borg dyspnea scores during exercise, locus of symptom limi-
tation, and safety measures were assessed.
Results: Aclidinium significantly improved ET on Day 1 (P Z 0.0002), and improvements were
sustained through Week 3 (P Z 0.0007) and Week 6 (P Z 0.0042) vs placebo. Compared with
placebo, aclidinium improved trough FEV1, IC, and IC/TLC at Weeks 3 and 6 (P < 0.05 for all).
Exertional dyspnea scores at isotime were reduced on Day 1, Week 3, and Week 6 for aclidi-
nium vs placebo (P < 0.05). Furthermore, the likelihood of stopping exercise due to breathingneumologie, Institut Universitaire de cardiologie et de pneumologie de Que´bec, 2725 Chemin Sainte-
þ1 418 656 4747; fax: þ1 418 656 4762.
med.ulaval.ca (F. Maltais).
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Aclidinium improves endurance time and hyperinflation 581discomfort was lower in the aclidinium group at study end (P Z 0.0208) compared with
placebo. No differences in safety outcomes were reported between treatments.
Conclusions: Aclidinium significantly increased exercise tolerance, improved airflow obstruc-
tion and lung hyperinflation, and was safe and well tolerated.
Registration of Trial: This trial was registered with ClinicalTrials.gov (NCT00500318) under the
name “A Study of Exercise Endurance and Lung Hyperinflation in Patients with Moderate to
Severe COPD”.
ª 2010 Elsevier Ltd. All rights reserved.f GENUAIR is a registered trademark of Almirall, S.A.Introduction
Chronic obstructive pulmonary disease (COPD) is a major
cause of mortality worldwide.1e4 It is a preventable and
treatable disease associated with progressive decreases in
forced expiratory volume in 1 s (FEV1) accompanied by lung
hyperinflation and exertional dyspnea.5
Reduced expiratory airflow is the hallmark of COPD.
Together with decreased lung elastic recoil, this leads to
lung hyperinflation that is worsened by exacerbations and
the progression of COPD.6,7 Static hyperinflation is associ-
ated with increased mortality8 while exercise-induced or
dynamic hyperinflation significantly limits exercise capacity
and is associated with breathlessness9e11 and reduced
ability to complete daily living activities.6,12,13
Improvements in exercise endurance, lung mechanics
and alleviation of dyspnea are important therapeutic goals
in COPD.3 Short-acting14 and long-acting bronchodila-
tors15,16 have been shown to improve lung function, mini-
mize dynamic hyperinflation and correspondingly increase
exercise endurance time (ET).9,15 Tiotropium bromide is
currently the only available long-acting anticholinergic for
COPD.17,18 As patient responses may vary, additional
treatment options are warranted.
Aclidinium bromide is a novel, inhaled, long-acting
muscarinic antagonist currently in Phase III development
for COPD. Sustained 24-h bronchodilation and favorable
tolerability have been demonstrated with aclidinium in
COPD patients.19,20 Aclidinium is rapidly hydrolyzed to two
major inactive metabolites,21e23 and its low circulating
concentration following inhalation suggests a reduced
potential for systemic side effects. We hypothesized that
aclidinium would improve airflow limitation and decrease
lung hyperinflation, thereby increasing exercise tolerance
in COPD patients. The purpose of this study was to examine
the effect of once-daily aclidinium 200 mg on exercise
endurance and lung hyperinflation during cycle ergometry,
and assess its safety and tolerability in moderate to severe
COPD patients.
Methods
Study design
This 6-week, Phase III, randomized, double-blind, placebo-
controlled study was conducted in 52 centers (42 US, 10
Canada) according to ICH Good Clinical Practice guidelines
and the Declaration of Helsinki and approved by local
ethics committees. Following a 2-week run-in, patients
were randomized (1:1) to aclidinium 200 mg or placeboonce-daily, administered via inhalation through a novel,
multidose dry powder inhaler (Genuair),f for 6 weeks.
Pulmonary function tests and cycle ergometry performed at
study visits (screening, run-in, randomization, Weeks 3 and
6) evaluated bronchodilation and exercise response.
Patients gave written informed consent prior to any study
procedure.
Study subjects
Participants included males and females 40 years, current
and ex-smokers with a smoking history 10 pack-years,
clinical diagnosis of moderate to severe stable COPD
(post-bronchodilator FEV1/forced vital capacity [FVC]< 70%
and FEV1 30% and <80% predicted), functional residual
capacity (FRC)  120% predicted at screening, and baseline
dyspnea index (BDI) focal score 7. Subjects were excluded
if previously hospitalized for an acute COPD exacerbation3
months pre-screening, or had a respiratory tract infection
or COPD exacerbation 6 weeks pre-screening. Patients with
a history of asthma, allergic rhinitis or atopy; contraindica-
tions to clinical exercise testing according to the American
Thoracic Society (2003); cycled 20 min during constant
work-rate exercise tests during run-in; or participated in
current or previous COPD rehabilitation programs 6 weeks
pre-randomization were also excluded. Levalbuterol (US) or
salbutamol (Canada) was allowed as needed, 6 h before
each visit. Inhaled, oral or parenteral corticosteroids at
doses 10 mg/day or 20 mg every other day were allowed if
use was stable 4 weeks before screening. No other COPD
medications were allowed throughout the trial. Oxygen
therapy was allowed as needed15 h/day but not within 2 h
of study visits.
Assessments
Spirometry (FEV1, FVC, inspiratory capacity [IC], and vital
capacity [VC]) and body plethysmography (FRC, total lung
capacity [TLC] and residual volume [RV]) were performed
pre-dose (trough) and 2 h post-administration of study
medication during study visits. Breathlessness at rest was
measured at baseline by the Baseline Dyspnea Index (BDI),
and at Weeks 3 and 6 by the transitional dypsnea index
(TDI).24 Symptom-limited cycle ergometry during screening
determined peak work rate (Wmax), the highest work rate
maintained for 30 s. After 3 min of unloaded pedaling, the
work rate was increased in a stepwise manner in
582 F. Maltais et al.increments of 10 watts/min, starting at 10 W, until toler-
ance limit. Constant work rate cycle ergometry at 75%Wmax
was performed 2 times during run-in to familiarize subjects
with study procedures, and at 3 h post-administration of
the study medication at randomization and Weeks 3 and 6.
After 1 min of unloaded pedaling, the work rate was
increased to 75% Wmax and subjects were encouraged to
cycle to the point of symptom limitation. ET was defined as
time from increase in work rate to 75% Wmax to point of
symptom limitation. Subjects rated intensity of dyspnea
and leg discomfort using the modified Borg scale, and the
locus of symptom limitation (dyspnea, leg fatigue, or their
combination) was evaluated. Ventilatory responses to
exercise and dynamic hyperinflation were evaluated at
rest, isotime (defined for each subject as the minimum ET
among the constant work rate tests at 75% Wmax at each
study visit), and end of exercise using a commercially
available exercise circuit system, in addition to blood
pressure and electrocardiograms (ECGs). Baseline values
were obtained during the second constant work rate cycle
ergometry performed during run-in.
Endpoints
The primary efficacy endpoint was change in ET from
baseline to Week 6. Secondary efficacy endpoints included
changes in ET from baseline to Day 1 (randomization) and
Week 3, and changes in trough FEV1, IC, FRC, IC/TLC from
baseline to Day 1, Week 3 and Week 6. Additional efficacy
endpoints were assessed throughout the study, including
changes from baseline in exercise measures of IC and
breathing pattern, dyspnea and leg discomfort.
Safety and tolerability were assessed by monitoring
adverse events (AEs), exacerbations, vital signs, physical
examinations, laboratory tests (hematology, chemistry,
urinalysis), and ECGs.
Statistical analysis
Analyses of efficacy endpoints were performed on the
intent-to-treat (ITT) population, defined as patients in the
safety population with a baseline value and 1 post-base-
line assessment of ET. Efficacy endpoints were analyzed
using analysis of covariance (ANCOVA), with treatment and
center as factors, and baseline values as covariate. Treat-
ment effects are presented as least-square (LS) means and
standard errors (SE), adjusted for center and baseline.
Analyses of safety outcomes were performed on the safety
population, which consisted of patients who received 1
dose of study drug. A total sample size of 266 patients was
planned to provide at least 80% power to detect a statisti-
cally significant difference of 100 s between aclidinium and
placebo in the primary endpoint, assuming a 0.05 two-sided
Type I error and a common SD of 290 s.
Results
Patient demographics and baseline characteristics
A total of 587 moderate-to-severe COPD patients were
screened and 181 patients were randomized to aclidinium(n Z 86) or placebo (n Z 95; Fig. 1). Most of the screening
failures were due to patient’s personal request (46/406) or
non-fulfillment of inclusion or exclusion criteria (309/406), of
which the most frequent were FRC not 120% (nZ 115) and
post-bronchodilator FEV1 not 30% and <80% of predicted
(n Z 47; Fig. 1). Baseline demographic characteristics were
similar across groups (Table 1). A total of 159 patients
completed the study. More patients with placebo dis-
continued the study vs aclidinium (17.9% vs 5.8%, respec-
tively). The most common reason for discontinuation was AEs
(nZ 8 and nZ 3 for placebo and aclidinium, respectively).
The safety population comprised all 181 randomized patients.
One patient randomized to placebo did not have baseline and
post-baseline ET, and was not included in the ITT population.
Exercise endurance
The adjustedmean (SE) change in ET from baseline toWeek 6
was significantly greater for aclidinium than placebo (129
[31] s vs 13 [31] s, respectively), with a difference between
treatment groups of 116 (40) s (P Z 0.0042; Fig. 2). This
effect was observed across time with adjusted mean treat-
ment differences (SE) in ET between aclidinium and placebo
on Day 1 and Week 3 equal to 143 (37) s and 126 (36) s,
respectively (PZ 0.0001 for both).
Resting lung function, hyperinflation and dyspnea
Aclidinium increased adjusted mean trough FEV1 from base-
line to Weeks 3 and 6, while slight decreases were observed
with placebo (Fig. 3). These changes from baseline were
significantly higher for aclidinium over placebo at Weeks
3 and 6 (P < 0.0001 for both). Treatment differences in
changes from baseline in trough IC were significantly in favor
of aclidinium at Week 3 (P < 0.01) and Week 6 (P < 0.05;
Fig. 3). Significant treatment differences in favor of aclidi-
nium were similarly observed for IC/TLC (P < 0.01 and
P< 0.05 forWeeks 3 and 6, respectively). The adjustedmean
trough FRC decreased from baseline at Weeks 3 and 6 with
both treatments, with no significant difference between
groups (Fig. 3). Improvements in resting lung function
parameters at 2 h after administration of study medication
were significantly greater with aclidinium vs placebo
throughout the study (Fig. 3). Significant improvements in
dyspneawere observedwith aclidinium vs placebo atWeeks 3
and6,with improvements in adjustedmeanTDI scores of 1.19
(PZ 0.005) and 1.71 (PZ 0.0004) units, respectively.
Operating lung volumes and ventilatory responses
to exercise
Adjusted mean changes from baseline in IC at rest, isotime
and peak were numerically higher for aclidinium than
placebo on Week 6, with significant treatment differences
in favor of aclidinium at Day 1 and Week 3 (P < 0.05 for all;
Table 2). Aclidinium significantly increased inspiratory
reserve volume (IRV) from baseline at rest, isotime and
peak vs placebo on Day 1 (P < 0.01 for all). Improvements in
IRV were also observed with aclidinium at Weeks 3 and 6,
but these were generally not statistically significant vs
placebo. Aclidinium was also associated with a significant
increase from baseline in VT at both isotime and peak vs
Figure 1 Study flow chart.
Aclidinium improves endurance time and hyperinflation 583placebo at all visits. On other outcomes (RR, V0E), there was
a general trend towards improvement with aclidinium,
although differences did not reach statistical significance at
most time points.Table 1 Baseline demographics and clinical characteristics at s
Variables
Age, years
Male, n (%)
Caucasian, n (%)
BMI, kg/m2
Current smoker, n (%)
Smoking history, pack-years
Pulmonary function (spirometry and body plethysmography)
Pre-bronchodilator FEV1, L
Post-bronchodilator FEV1, L
Post-bronchodilator FEV1, % predicted
Post-bronchodilator FVC, L
Post-bronchodilator FEV1/FVC ratio, %
FRC, L
FRC, % predicted
TLC, L
IC,b L
RV, L
Peak values during incremental exercise
Wmax, Watts
RR, breaths/min
V0O2, L/min
V0CO2, L/min
V0E, L/min
VT, L
BMI, body-mass index, FEV1, forced expiratory volume in 1 s; FVC, fo
lung capacity; IC, inspiratory capacity; RV, residual volume; Wmax, p
V0CO2, carbon dioxide output; V0E, minute ventilation; VT, tidal volum
a Data are in adjusted mean (SD), unless otherwise indicated.
b Measured during the run-in period (Day e10).Exertional dypsnea and leg discomfort
Aclidinium significantly improved exertional dypsnea at iso-
time, with a decrease over placebo >1 Borg unit on Day 1 andcreening (safety population).a
Aclidinium 200 mg Placebo
(n Z 86) (n Z 95)
64.0 (9.5) 65.6 (7.8)
52 (60.5) 53 (55.8)
83 (96.5) 92 (96.8)
26.2 (4.6) 26.6 (4.7)
38 (44.2) 31 (32.6)
56.5 (25.0) 54.4 (21.1)
1.18 (0.44) 1.29 (0.43)
1.43 (0.50) 1.48 (0.48)
49.0 (10.6) 52.3 (13.5)
3.28 (1.03) 3.14 (0.85)
44.7 (9.8) 47.4 (9.9)
5.12 (1.23) 4.85 (1.24)
158.6 (29.6) 151.9 (32.5)
6.85 (1.56) 6.68 (1.47)
1.96 (0.67) 1.97 (0.54)
4.27 (1.25) 4.10 (1.27)
65 (25) 66 (24)
32.5 (6.6) 33.5 (8.5)
1.20 (0.88) 1.10 (0.37)
1.22 (0.84) 1.21 (0.98)
40.2 (13.1) 39.7 (12.8)
1.32 (0.52) 1.28 (0.46)
rced vital capacity; FRC, functional residual capacity; TLC, total
eak work rate; RR, respiratory rate; V0O2, oxygen consumption;
e.
Figure 2 Adjusted mean (SE) change from baseline in
endurance time (ET) throughout the study.
584 F. Maltais et al.Week 3 (P < 0.0001 for both), and 0.70 Borg unit at Week 6
(P < 0.05; Table 2). Improvement in ET correlated with the
reduction in Borg dypsnea scores at isotime (r Z 0.342,
PZ0.0022)andan increased ICat isotime(rZ0.218,PZ0.06)
following aclidinium treatment. Legdiscomfortwasdiminished
at isotime at Day 1 (P < 0.01) and Week 3 (P < 0.05), and at
peak at Week 6 (P< 0.05; Table 2). The probability of stopping
exercise because of breathing discomfort was significantly
lower with aclidinium vs placebo atWeek 6 (odds ratioZ 0.45,
PZ 0.02).Figure 3 Mean (SE) change from baseline in resting lung flow rate
6 (left and right panels, respectively).Safety
Aclidinium 200 mg was well tolerated, with a safety
profile similar to placebo after 6 weeks of treatment.
Treatment-emergent AEs (TEAEs) were reported in 57.0%
and 46.3% of aclidinium- and placebo-treated patients,
respectively. TEAEs reported by >3.0% of patients in either
treatment group are shown in Table 3. Themajority of TEAEs
weremild ormoderate in both groups. The only report of dry
mouth was in the placebo group (n Z 1). Five patients
experienced serious adverse events (SAEs); none were fatal
or deemed to be study drug-related. SAEs were reported by
2/86 (2.3%) patients in the aclidinium group compared with
3/95 (3.2%) placebo-treated patients. No cardiac or cere-
brovascular AEs were reported. Laboratory tests, vital signs
and ECG findings were similar between treatment groups.
Discussion
This study demonstrates that treatment of moderate-to-
severe COPD patients with aclidinium bromide 200 mg once-
daily for 6 weeks improved exercise ET and reduced lung
hyperinflation and dyspnea. Improving exercise tolerance
and alleviating lung hyperinflation and dyspnea are impor-
tant goals in the therapeutic management of COPD and
can help improve quality of life.9,15 Although the current
proposal for what is the minimum clinically importants and volumes at trough (A) and 2 h post-dose (B) at Weeks 3 and
Table 2 LS mean (95% confidence interval) treatment differences (aclidinium e placebo) in change from baselinea in exercise
measures throughout the study (ITT population).a
Day 1 Week 3 Week 6
IC, L
Rest 0.272 (0.162, 0.383)b 0.227 (0.114, 0.340)b 0.037 (0.103, 0.177)
Isotime 0.242 (0.136, 0.349)b 0.167 (0.056, 0.279)c 0.0427 (0.092, 0.177)
Peak 0.259 (0.156, 0.362)b 0.110 (0.002, 0.217)d 0.015 (0.115, 0.145)
IRV, L
Rest 0.241 (0.105, 0.377)b 0.232 (0.105, 0.359)b 0.124 (0.030. 0.278)
Isotime 0.147 (0.038, 0.257)c 0.018 (0.087, 0.123) 0.053 (0.180, 0.074)
Peak 0.162 (0.057, 0.266)c 0.018 (0.120, 0.085) 0.064 (0.188, 0.059)
VT, L
Rest 0.052 (0.053, 0.157) 0.016 (0.089, 0.056) 0.077 (0.147, 0.008)d
Isotime 0.143 (0.091, 0.195)b 0.126 (0.078, 0.174)b 0.111 (0.056, 0.167)b
Peak 0.124 (0.074, 0.173)b 0.106 (0.053, 0.159)b 0.098 (0.042, 0.154)b
V0E, L/min
Rest 1.454 (0.159, 2.750)d 0.106 (0.986, 1.198) 1.518 (1.135, 4.172)
Isotime 0.692 (0.717, 2.101) 1.098 (0.797, 2.992) 1.019 (0.601, 2.639)
Peak 1.158 (0.507, 2.823) 7.171 (23.771, 9.428) 1.888 (0.100, 3.676)d
RR, breaths/min
Rest 0.364 (0.969, 1.697) 0.734 (0.563, 2.031) 0.918 (0.262, 2.097)
Isotime 2.602 (3.898, 1.307)b 1.235 (2.648, 0.177) 0.989 (2.333, 0.355)
Peak 0.840 (2.104, 0.425) 0.181 (1.358, 1.721) 0.291 (1.723, 1.141)
Dyspnea, Borg
Rest 0.149 (0.365, 0.068) 0.124 (0.359, 0.111) 0.014 (0.166, 0.194)
Isotime 1.142 (1.688, 0.596)b 1.197 (1.730, 0.664)b 0.704 (1.258, 0.151)d
Peak 0.159 (0.651, 0.332) 0.655 (1.228, 0.082)d 0.034 (0.564, 0.497)
Leg discomfort, Borg
Rest 0.146 (0.425, 0.133) 0.084 (0.337, 0.169) 0.050 (0.138, 0.239)
Isotime 0.853 (1.374, 0.333)c 0.603 (1.12, 0.090)d 0.466 (1.042, 0.111)
Peak 0.214 (0.331, 0.760) 0.392 (0.225, 1.009) 0.636 (0.122, 1.151)d
ITT, intent-to-treat population; IC, inspiratory capacity; IRV, inspiratory residual volume; VT, tidal volume; V
0
E, minute ventilation; RR,
respiratory rate.
a Day 10 data were used for baseline values if Day e5 data were not available.
b P < 0.001 vs placebo.
c P < 0.01 vs placebo.
d P < 0.05 vs placebo.
Aclidinium improves endurance time and hyperinflation 585difference (MCID) for the constant work rate cycle exercise
test should not be viewed as definitive, the improvement in
ET throughout 6 weeks of aclidinium treatment (116e143 s)
reported here is above the suggested value of 105 s.25Table 3 Adverse events reported by >3% of subjects in either
Adverse event
Headache
COPD exacerbation
Cough
Upper respiratory tract infection
Nasopharyngitis
Back pain
Urinary tract infection
Pharyngolaryngeal pain
Dyspepsia
Dyspnea
Sinus congestionA change of 100e200 s in ET has also been associated
with clinically significant improvements in health status.26
The treatment effect in ET after 6 weeks of aclidinium
treatment is comparable to that observed in two 6-weektreatment group.
Aclidinium 200 mg
(n Z 86)
n (%)
Placebo
(n Z 95)
n (%)
5 (5.8) 7 (7.4)
2 (2.3) 7 (7.4)
5 (5.8) 3 (3.2)
5 (5.8) 2 (2.1)
4 (4.7) 2 (2.1)
3 (3.5) 3 (3.2)
2 (2.3) 4 (4.2)
3 (3.5) 1 (1.1)
3 (3.5) 1 (1.1)
1 (1.2) 3 (3.2)
0 4 (4.2)
586 F. Maltais et al.studies with tiotropium (100e105 s, when the median
increase in ET is used in one of the studies16 due to outliers
with ET>3000 s)15,16 and an 8-week study with salmeterol/
fluticasone (132 s).27 However, the increase in ET with
tiotropium was observed over time, with the maximal
effect at the end of the study. In contrast, the maximal
effect on ET in the current aclidinium study was observed
after the first day of treatment. A slight decrease in effect
was observed between Day 1 and Week 3, but overall, the
improvement in ET with aclidinium was maintained
throughout the 6-week study.
A clinically significant improvement vs placebo in
trough FEV1 (101 mL) was observed after 6 weeks with
aclidinium, which is greater than that observed in earlier
aclidinium Phase III studies (60e70 mL).19,20 This may have
been due to differences between study populations since
inclusion criteria in the current study had additional
requirements regarding lung hyperinflation and the
minimum baseline dyspnea level. Statistically significant
and clinically relevant improvements in various lung
function parameters observed on Day 1 until Week 6
indicate that aclidinium efficacy occurred on the first day
of administration and was sustained until the end of the
study.
Dynamic hyperinflation is a critical factor in the wors-
ening of exertional dyspnea and reduced exercise capacity
in COPD.10 Aclidinium significantly improved IC measured
at isotime (>200 mL) at Day 1 and Week 3, suggesting
a beneficial effect on dynamic hyperinflation. It is unclear
why changes in dynamic hyperinflation were no longer
statistically significant at Week 6, since the beneficial
effects of the medication on resting lung function and
breathing pattern during exercise were maintained through
Week 6. However, technical issues should not be ruled out,
as repeated measurements of IC may be challenging to
perform consistently in a large multicenter trial. Resting
lung hyperinflation is associated with higher mortality8 and
reduced exercise capacity.28 In this study, aclidinium
improved resting lung hyperinflation, demonstrated by the
significant improvements in trough IC and trough IC/TLC
and a positive trend for FRC at study end. The magnitude of
improvements in resting IC reported here is similar to those
reported for aclidinium Phase III studies19,20 and a 6-week
tiotropium study.15
Aclidinium provided clinically relevant reductions in
dyspnea29 at the end of the study, demonstrated by signif-
icant improvements in functional dyspnea (difference in TDI
focal scores of 1.71 units over placebo) and exercise-related
dyspnea (0.7 Borg units at isotime over placebo).
The tolerability and favorable safety profile of aclidinium
was supported by the low incidence of anticholinergic AEs in
this study such as dry mouth, and similar rates of TEAEs
and SAEs between groups. There was also no evidence for
increased cardiovascular TEAEs. This may be due to rapid
plasma hydrolysis of aclidinium and its low systemic
bioavailability demonstrated in earlier studies.21e23
One potential limitation of this trial is that we could not
reach the target sample size. Although it was initially
planned to enroll 266 patients, the study was stopped early
due to difficulty recruiting patients. However, the final
observed difference in ET of 116 s was larger than the
target difference of 100 s, clearly confirming that the studywas positive. In addition, although the relatively short
treatment time prevented observations of effect duration,
there was little change between Weeks 3 and 6 of this
study.
Overall, aclidinium bromide 200 mg once-daily signifi-
cantly improved exercise tolerance and dyspnea both at
rest and during exercise, and was safe and well tolerated.
The maximum treatment effect was seen after only one
dose, and the statistically significant effect was maintained
for 6 weeks. Aclidinium also provided clinically significant
bronchodilation and reduced lung hyperinflation and
therefore may be a valuable new option for the treatment
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